Physician profile
Breton N Roussel
NPI 1215385661
$49,888.18
in general payments reported to CMS, 2019-2025
22 companies · $40K in 2025
The $40K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $57.96 · 2021: $165 · 2022: $129 · 2023: $499 · 2024: $9,376 · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40K · Food and Beverage: $7,170 · Travel and Lodging: $1,953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40,413.86 |
| Food and Beverage | $7,169.50 |
| Travel and Lodging | $1,952.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $29,702.66 | 2020-2025 | Tremfya, Stelara |
| Phathom Pharmaceuticals, INC. | $15,551.24 | 2024-2025 | Voquezna |
| Abbvie INC. | $1,153.61 | 2023-2025 | Skyrizi, Linzess, Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $682.83 | 2023-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $523.66 | 2024-2025 | Xifaxan, Trulance |
| Intercept Pharmaceuticals, INC. | $339.40 | 2023-2025 | Ocaliva |
| Medtronic, INC. | $254.82 | 2021-2022 | |
| Ardelyx, INC. | $230.90 | 2023-2025 | Ibsrela |
| Gilead Sciences, INC. | $230.19 | 2023-2025 | |
| Celgene Corporation | $206.89 | 2023-2024 | Zeposia |
| Pfizer INC. | $179.49 | 2024-2025 | |
| Lilly USA, LLC | $157.97 | 2023-2024 | Omvoh |
| Braintree Laboratories, INC. | $151.11 | 2025 | Suflave, Sutab |
| Novo Nordisk INC | $150.39 | 2023-2025 | Wegovy |
| Ironwood Pharmaceuticals, INC | $97.34 | 2023-2024 | Linzess |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $84.33 | 2024 | Iqirvo |
| Madrigal Pharmaceuticals | $58.85 | 2024-2025 | Resmetirom, Rezdiffra |
| Ferring Pharmaceuticals INC. | $49.16 | 2023-2024 | Rebyota |
| Boston Scientific Corporation | $23.29 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.87 | 2023 | Cyltezo |
| Regeneron Healthcare Solutions, INC. | $19.05 | 2024 | Dupixent |
| Orphalan INC | $18.13 | 2025 | Cuvrior |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Breton Roussel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.